LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Aandelen Lijst・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

70.03 3.02

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

66.23

Max

70.99

Belangrijke statistieken
By Trading Economics
Inkomsten	24M -167M
Verkoop	40M 195M
EPS	-0.84
Winstmarge	-85.626
Werknemers	834
EBITDA	75M -105M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+58.14% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-581M 13B
Vorige openingsprijs	67.01
Vorige sluitingsprijs	70.03

Nieuwssentiment

By Acuity

100%

111 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.71 / 36.9 Steun & Weerstand

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 mei 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mei 2026, 16:49 UTC

Winsten

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mei 2026, 16:26 UTC

Belangrijke Marktbewegers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mei 2026, 23:51 UTC

Marktinformatie

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mei 2026, 22:33 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mei 2026, 21:53 UTC

Winsten

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mei 2026, 21:02 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mei 2026, 20:55 UTC

Winsten

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mei 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mei 2026, 20:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 mei 2026, 20:20 UTC

Marktinformatie

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Adj EPS 3c >BULL

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Rev $159.9M >BULL

21 mei 2026, 20:18 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mei 2026, 20:18 UTC

Winsten

Webull 1Q Loss/Shr 4c

21 mei 2026, 19:43 UTC

Marktinformatie

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mei 2026, 18:58 UTC

Winsten

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mei 2026, 18:15 UTC

Marktinformatie

Gold Higher For Second Consecutive Day -- Market Talk

21 mei 2026, 17:40 UTC

Marktinformatie

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mei 2026, 17:04 UTC

Marktinformatie

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mei 2026, 17:01 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Stellantis Targets Distant but Constructive -- Market Talk

21 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

58.14% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.88 USD 58.14%

Hoogste 157 USD

Laagste 82 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.71 / 36.9Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

111 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.